Raymond James & Associates Aerie Pharmaceuticals Inc Transaction History

Raymond James & Associates

$146 Billion
Q1 2024

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 02, 2021	SELL	$11.32 - $16.63 $482,933 - $709,469	-42,662 Closed	0 $0
Q2 2021 Aug 11, 2021	BUY	$15.16 - $18.97 $13,856 - $17,338	914 Added 2.19%	42,662 $683,000
Q1 2021 May 14, 2021	BUY	$13.12 - $20.9 $14,773 - $23,533	1,126 Added 2.77%	41,748 $746,000
Q4 2020 Feb 12, 2021	SELL	$9.12 - $14.49 $282 - $449	-31 Reduced 0.08%	40,622 $549,000
Q3 2020 Nov 04, 2020	SELL	$10.46 - $14.46 $16,600 - $22,948	-1,587 Reduced 3.76%	40,653 $478,000

Q2 2020 Jul 28, 2020	BUY	$12.0 - $16.13 $2,580 - $3,467	215 Added 0.51%	42,240 $623,000
Q1 2020 Apr 21, 2020	BUY	$11.84 - $25.52 $87,485 - $188,567	7,389 Added 21.33%	42,025 $567,000
Q4 2019 Feb 12, 2020	SELL	$17.72 - $25.1 $277,867 - $393,593	-15,681 Reduced 31.16%	34,636 $837,000
Q3 2019 Nov 07, 2019	BUY	$18.41 - $28.0 $717 - $1,092	39 Added 0.08%	50,317 $967,000
Q2 2019 Aug 06, 2019	BUY	$28.97 - $48.21 $1.46 Million - $2.42 Million	50,278 New	50,278 $1.49 Million
Q4 2018 Feb 11, 2019	SELL	$33.0 - $60.04 $566,775 - $1.03 Million	-17,175 Closed	0 $0
Q3 2018 Nov 14, 2018	SELL	$56.15 - $73.9 $471,603 - $620,686	-8,399 Reduced 32.84%	17,175 $1.06 Million
Q2 2018 Aug 14, 2018	BUY	$47.85 - $70.45 $5,742 - $8,454	120 Added 0.47%	25,574 $1.73 Million
Q1 2018 May 14, 2018	SELL	$51.15 - $61.0 $1.61 Million - $1.92 Million	-31,440 Reduced 55.26%	25,454 $1.38 Million
Q4 2017 Feb 14, 2018	SELL	$50.85 - $65.1 $88,428 - $113,208	-1,739 Reduced 2.97%	56,894 $3.4 Million
Q3 2017 Nov 13, 2017	BUY	$48.6 - $60.1 $38,491 - $47,599	792 Added 1.37%	58,633 $2.85 Million
Q2 2017 Aug 14, 2017	BUY	N/A	57,841	57,841 $3.04 Million

Others Institutions Holding AERI

# of Institutions

Shares Held

2.4M

Call Options Held

Put Options Held

View Full List

About AERIE PHARMACEUTICALS INC

Ticker AERI
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 49,390,500
Description
Aerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular p...

More about AERI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

News

Stay updated on Raymond James & Associates with notifications on news.

Account